A Phase I/II Study of IOV-4001 in People with Inoperable or Metastatic Melanoma or Non-Small Cell Lung Cancer
Source: Memories Sloan Kettering Cancer Centre, September 2022
Full Title
A Phase 1/2, Open-label Study of PD-1 Knockout Tumor-infiltrating Lymphocytes (IOV-4001) in Participants with Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Purpose
The purpose of this study is to assess the safety and effectiveness of the investigational treatment IOV-4001, a form of immunotherapy called “tumor-infiltrating lymphocyte (TIL) therapy,” in people with inoperable or metastatic melanoma or non-small cell lung cancer. IOV-4001 is made from white blood cells (lymphocytes or T cells) that come from a piece of a patient’s own tumor, which was removed during surgery. The TILs are developed further in a laboratory, then delivered back to the patient several weeks later. TIL treatments are designed to help the immune system destroy cancer cells. IOV-4001 is given intravenously (by vein).